Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Daniel S Chen"'
Autor:
James L Gulley, James Larkin, Leisha A Emens, Mario Sznol, Madhav Dhodapkar, Daniel S Chen, Roy S Herbst, Tim F Greten, Robert L Ferris, Luca Mazzarella, Paolo A Ascierto, Marc S Ernstoff, Michael B Atkins, Kim A Margolin, Brian I Rini, Michael R Bishop, Suresh S Ramalingam, Meredith M Regan, Rachel W Humphrey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal p
Externí odkaz:
https://doaj.org/article/924c88f5ec8f4838a91c8255c8c43862
Autor:
Chiung-Hung Chang, Bi Yu, Chiu-Hsian Su, Daniel S Chen, Yu-Chi Hou, Yueh-Sheng Chen, Yuan-Man Hsu
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105362 (2014)
Salmonella, a common zoonotic pathogen, causes gastroenteritis in both humans and animals. Traditional Chinese Medicine (TCM) has been used to improve gastrointestinal dysfunction and to modify the immune response to inflammation for centuries. This
Externí odkaz:
https://doaj.org/article/24550bc15c5941fc88014e19263f20f6
Autor:
Elizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, Heidi Savage, Ajay Pandita, Ru-Fang Yeh, Andrea Pirzkall, Bernard M Fine, Lukas C Amler, Daniel S Chen, Mark R Lackner
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12517 (2010)
Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a relatively non-invasive source of representative tumor material. Circulating Tumor Cells (CTCs) isolated from blood of metastatic cancer patient
Externí odkaz:
https://doaj.org/article/f38c38ef1872463483198588d1a90475
Autor:
Daniel S Chen, Yoav Soen, Tor B Stuge, Peter P Lee, Jeffrey S Weber, Patrick O Brown, Mark M Davis
Publikováno v:
PLoS Medicine, Vol 2, Iss 10, p e265 (2005)
BackgroundIn contrast to many animal model studies, immunotherapeutic trials in humans suffering from cancer invariably result in a broad range of outcomes, from long-lasting remissions to no discernable effect.Methods and findingsIn order to study t
Externí odkaz:
https://doaj.org/article/2d393b24e4b74f30aee22a64584a7cd9
Publikováno v:
PLoS Biology, Vol 1, Iss 3, p E65 (2003)
The detection and characterization of antigen-specific T cell populations is critical for understanding the development and physiology of the immune system and its responses in health and disease. We have developed and tested a method that uses array
Externí odkaz:
https://doaj.org/article/b166588744e2412db3b5ca723d34aa5d
Autor:
Daniel S. Chen, Stefan J. Scherer, Rebecca Elliott, Coen Bernaards, Y. Gloria Meng, Nicole F. Li, Dafeng Chen, Adrian M. Jubb, Priti S. Hegde
PDF file - 234K, Baseline demographics for patients with and without VEGF-A samples in the AVF2107, E4599, AVAiL, and AVOREN trials, The GEN.038 VEGF-A ELISA, Standard curves for different VEGF-A isoforms in the GEN.038 assay, Correlation of baseline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2907964628f99f116fd4205da225951
https://doi.org/10.1158/1078-0432.22448259
https://doi.org/10.1158/1078-0432.22448259
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Purpose:Atezolizumab [anti–programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity. We evaluated the long-term safety and act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10746515c079c17f9a6ccbb5603f4804
https://doi.org/10.1158/1078-0432.c.6527925.v1
https://doi.org/10.1158/1078-0432.c.6527925.v1
Autor:
Hartmut Koeppen, Daniel S. Chen, Kenneth J. Hillan, Virginia K. Langmuir, Maike Schmidt, Melody A. Cobleigh, James D. Reimann, Dafeng Chen, Adrian L. Harris, Hope S. Rugo, Kathy D. Miller, Adrian M. Jubb
Purpose: The addition of bevacizumab to cytotoxic chemotherapy has demonstrated a progression-free survival (PFS) benefit in the first-line and second-line treatment of advanced or metastatic breast cancer (MBC). However, the addition of bevacizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5f88df21e4a07d7583cd33ddec4620
https://doi.org/10.1158/1078-0432.c.6520133
https://doi.org/10.1158/1078-0432.c.6520133
Autor:
F. Stephen Hodi, Priti S. Hegde, Daniel S. Chen, Carol O'Hear, Marcella Fassò, Marcus Ballinger, Indrani Sarkar, John D. Powderly, David F. McDermott, Harriet M. Kluger, Eva Muñoz-Couselo, Jeffrey A. Sosman, Christopher R. Bolen, Luciana Molinero, Omid Hamid
Figures S1-S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ed4fcdf75666e00700454e15846c60
https://doi.org/10.1158/1078-0432.22471542
https://doi.org/10.1158/1078-0432.22471542
Autor:
Hartmut Koeppen, Daniel S. Chen, Kenneth J. Hillan, Virginia K. Langmuir, Maike Schmidt, Melody A. Cobleigh, James D. Reimann, Dafeng Chen, Adrian L. Harris, Hope S. Rugo, Kathy D. Miller, Adrian M. Jubb
Supplementary Figures S1-S3; Supplementary Tables S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a3d1175e530270e39e4f22d54cc6c34
https://doi.org/10.1158/1078-0432.22444337
https://doi.org/10.1158/1078-0432.22444337